Cost-effectiveness study of atezolizumab vs. durvalumab : real-world data on first-line chemotherapy combined with immune-checkpoint inhibitors for extensive disease small-cell lung cancer
Not Applicable
- Conditions
- extensive disease small cell lung cancer
- Registration Number
- JPRN-UMIN000053483
- Lead Sponsor
- Kobe Minimally Invasive Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Cases judged by researchers at each institution to be inappropriate for registration.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method